A. Ghorab

Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

Michael L. Wang, Shaojun Zhang, Linghua Wang, 2018, British journal of haematology.

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Cancer.

Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs

A. Tefferi, M. Shah, C. A. Yi, 2022, Blood cancer journal.

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

H. Kantarjian, J. Cortes, K. Patel, 2020, Blood Cancer Journal.

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

H. Kantarjian, J. Cortes, K. Patel, 2020, Blood Cancer Journal.

Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.

M. Konopleva, H. Kantarjian, J. Cortes, 2018 .